Surveillance for factor VIII inhibitor development in the Canadian hemophilia a population following the widespread introduction of recombinant factor VIII replacement therapy

Transfusion Science

Volumn 19, Issue 2, 1998, Pages 139-148

  Giles, A R ^a,b   Rivard, G E ^a   Teitel, J ^a   Walker, I ^a  

^a Assoc Hemophilia Ctr Directors C   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; CANADA; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEMOPHILIA A; HUMAN; POPULATION RESEARCH; SUBSTITUTION THERAPY;

CANADA; FACTOR VIII; HEMOPHILIA A; POPULATION SURVEILLANCE; RECOMBINANT PROTEINS;

EID: 0347662157     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00024-1     Document Type: Article

References (29)

1. Jones P: Management of haemophilia. Arch Disease in Childhood 1984; 59:1010-1012.
2. Kasper CK: Complications of hemophilia A treatment factor VIII inhibitors. Ann NY Acad Sci 1991; 614:97-105.
3. Rizza CR, Spooner RJD: Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: Report on behalf of the directors of haemophilia centres in the United Kingdom. Brit Med J 1983; 286:929-933.
4. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J: The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71:344-348.
5. Bloom AL: Factor VIII inhibitors revisited. Brit J Haematol 1981; 49:319-324.
6. Aledort LM: Lessons from hemophilia. New Engl J Med 1982; 306:607-608.
7. Ratnoff OD: Some complications of the therapy of classic hemophilia. J Lab Clin Med 1984; 103:653-659.
8. Gitschier J, Wood WI, Goralka TM, et al.: Characterisation of the human factor VIII gene. Nature 1984; 312:326-330.
9. Toole JJ, Knopf JM, Wozney JM, et al.: Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342-347.
10. Wood WI, Capon DJ, Simonsen CC, et al.: Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312:330-337.
11. Brownlee GG, Rizza CR: Clotting factor VIII cloned. Nature 1984; 312:307.
12. Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Ng P, Pancham N: The in vivo characterisation of recombinant factor VIII in a canine model of haemophilia A (Factor VIII deficiency). Blood 1988; 72:335-339.
13. White GCH, McMillan CW, Kingdon HS, Shoemaker CB: Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. New Engl J Med 1989; 320:166-170.
14. Brettler DB, Levine PH: Factor concentrates for treatment of hemophilia: which one to choose? Blood 1989; 73:2067-2073.
15. Schimpf K, Mannucci PM, Kreutz W, et al,: Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. New Engl J Med 1987; 316:918-922.
16. Gerritzen A, Schneweis KE, Brackmann H-H, et al.: Acute hepatitis A in haemophiliacs. Lancet 1992; 340:1231-1232.
17. Peerlinck K, Vermylen J: Acute hepatitis A in patients with haemophilia A. Lancet 1993; 341:179.
18. Kedda MA, Kew MC, Cohn RJ, et al.: An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as source. Hepatology 1995; 22(5):1363-1367.
19. Wion KL, Kelly D, Summerfield JA, Tuddenham EG D, Lawn RM: Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317:726-729.
20. Vehar GA, Keyt B, Eaton D, et al.: Structure of human factor VIII. Nature 1984; 312:337-342.
21. Erenforth S, Kreuz W, Scharrer I, et al.: Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 139:594-598.
22. Kasper CK, Aledort LM, Counts RB, et al.: Measurement A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:869-872.
23. Verbruggen B, Novakova I, Wessels H, et al.: The Nijmegan modification of the Bethesda assay for factor VIII:C inhibitors improved specificity and reliability. Thromb Haemostas 1995, 73:247-251.
24. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I: The Association of Heamophilia Centre Directors of Canada: A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemostas 1998; 79:872-875.
25. Giles AR, Hensmen C, Samis J: The Association of Hemophilia Centre Directors of Canada. Amulticentre study of F.VIII inhibitor assay performance using standardised versus non-standardised methodology. Manuscript in preparation.
26. Rosendaal FR, Nieuwenhuis HK, Van den Berg HM, et al.: A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81:2180-2186.
27. DiMichele DM, Aledort LM: Inhibitor development with post-licensure use of recombinant factor VIII (rF.VIII): The U.S. hemophilia region II experience. Thromb Haemostas 1997; Supplement: p. 87 (Abstract 350).
28. Rizza CR, Matthews JM: Effect of frequent factor VIII replacement on the level VIII antibodies in haemophiliacs. Brit J Haematol 1982; 52:13-24.
29. Lusher JM, Arkin S, Abilgaard CF, Schwartz RS: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. New Engl J Med 1993; 328:453-459.